精神分裂症谱系障碍中谷氨酸能与GABA能代谢物水平的1H-MRS荟萃分析
结果显示基底节Glx升高,未用药患者海马和背外侧前额叶Glx升高,首发精神病患者MCC的GABA降低,难治性精神分裂症患者MCC的Glx和Glu升高。结论提示兴奋/抑制平衡破坏可能与精神分裂症谱系障碍病理生理相关。
要点
- 基底节Glx水平在精神分裂症谱系障碍患者中升高(g=0.32)。
- 未用药患者海马和背外侧前额叶Glx水平升高。
- 首发精神病患者MCC的GABA水平降低(g=-0.40)。
核心结论
- 谷氨酸能代谢物水平升高和GABA水平降低提示兴奋/抑制平衡破坏可能与精神分裂症谱系障碍病理生理相关。
主要发现
- 整体组中基底节Glx水平升高(g=0.32;95% CI:0.18-0.45)。
- 未用药患者海马Glx水平升高(g=0.47;95% CI:0.21-0.73),背外侧前额叶Glx水平升高(g=0.25;95% CI:0.05-0.44)。
- 首发精神病组MCC的GABA水平降低(g=-0.40;95% CI:-0.62至-0.17)。
- 难治性精神分裂症组MCC的Glx升高(g=0.7;95% CI:0.38-1.01),Glu升高(g=0.63;95% CI:0.31-0.94)。
- 非难治性患者组MCC的Glu水平降低(g=-0.17;95% CI:-0.33至-0.01)。
临床怎么用
- 1H-MRS测量的谷氨酸能和GABA能代谢物水平可能作为精神分裂症谱系障碍兴奋/抑制平衡异常的潜在生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The glutamate (Glu) and gamma aminobutyric acid (GABA) hypotheses of schizophrenia were proposed in the 1980s. However, current findings on those metabolite levels in schizophrenia have been inconsistent, and the relationship between their abnormalities and the pathophysiology of schizophrenia remains unclear. To summarize the nature of the alterations of glutamatergic and GABAergic systems in schizophrenia, we conducted meta-analyses of proton magnetic resonance spectroscopy (1H-MRS) studies examining these metabolite levels. METHODS: A systematic literature search was conducted using Embase, Medline, PsycINFO, and PubMed. Original studies that compared four metabolite levels (Glu, glutamine [Gln], Glx [Glu+Gln], and GABA), as measured by 1H-MRS, between individuals at high risk for psychosis, patients with first-episode psychosis, or patients with schizophrenia and healthy controls (HC) were included. A random-effects model was used to calculate the effect sizes for group differences in these metabolite levels of 18 regions of interest between the whole group or schizophrenia group and HC. Subgroup analysis and meta-regression were performed based on the status of antipsychotic treatment, illness stage, treatment resistance, and magnetic field strength. RESULTS: One-hundred-thirty-four studies met the eligibility criteria, totaling 7993 participants with SZ-spectrum disorders and 8744 HC. 14 out of 18 ROIs had enough numbers of studies to examine the group difference in the metabolite levels. In the whole group, Glx levels in the basal ganglia (g = 0.32; 95% CIs: 0.18-0.45) were elevated. Subgroup analyses showed elevated Glx levels in the hippocampus (g = 0.47; 95% CIs: 0.21-0.73) and dorsolateral prefrontal cortex (g = 0.25; 95% CIs: 0.05-0.44) in unmedicated patients than HC. GABA levels in the MCC were decreased in the first-episode psychosis group compared with HC (g = -0.40; 95% CIs: -0.62 to -0.17). Treatment-resistant schizophrenia (TRS) group had elevated Glx and Glu levels in the MCC (Glx: g = 0.7; 95% CIs: 0.38-1.01; Glu: g = 0.63; 95% CIs: 0.31-0.94) while MCC Glu levels were decreased in the patient group except TRS (g = -0.17; 95% CIs: -0.33 to -0.01). CONCLUSIONS: Increased glutamatergic metabolite levels and reduced GABA levels indicate that the disruption of excitatory/inhibitory balance may be related to the pathophysiology of schizophrenia-spectrum disorders.
引用
- Nakahara T, Tsugawa S, Noda Y, et al. Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of 1H-magnetic resonance spectroscopy studies. Mol Psychiatry. 2021. PMID: 34584230. doi:10.1038/s41380-021-01297-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。